# US 10,870,656 B2 · Methods for treatment of heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,656 B2
- Document ID: US10870656B2
- Status: Granted
- Kind: B2
- Application number: 16/240,393
- Filed: 2019-01-04
- Published: 2019-07-11
- Granted: 2020-12-22
- Earliest claimed: 2016-07-07
- Assignees: Cardurion Pharmaceuticals, LLC
- Applicants: Cardurion Pharmaceuticals, LLC
- Inventors: Michael E. Mendelsohn
- Web page: https://patentgrep.com/patent/US10870656B2

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods, compositions and kits for treating or preventing heart failure. Methods of the invention treating heart failure in a mammal comprising administering to the mammal an effective amount of a thienopyrimidine compound.

## Claims

### Claim 1

A method of treating heart failure in a mammal, the method comprising administering an effective amount of a compound having the structure
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the mammal is identified as exhibiting congestive heart failure.

### Claim 3 (depends on 2)

The method of claim 2 wherein the mammal has suffered from congestive heart failure disorder having low cardiac output and/or low stroke volume.

### Claim 4 (depends on 1)

The method of claim 1 claim wherein the mammal has suffered from cardiogenic shock.

### Claim 5 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 6 (depends on 5)

The method of claim 5 wherein the compound is co-administered with one or more Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers or Inhibitors; Angiotensin-Receptor Neprilysin Inhibitors (ARNIs; Beta Blockers; Aldosterone Antagonists; Diuretics; Anticoagulants (blood thinners); and/or Cholesterol lowering drugs.

### Claim 7 (depends on 1)

The method of claim 1 wherein the effective amount is from 0.01 to 10 mg/kg per day.

### Claim 8 (depends on 1)

The method of claim 1 wherein the compound is comprised in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The method of claim 8 wherein the pharmaceutical composition is formulated for administering purposes in a capsule, a tablet, a gel, a powder, liquid, suspension or emulsion.